I see the main risk as being non inclusion of Cvac on Healthcare organisation (whether that be government or insurance) approved drug lists. If the cost/benefit ratio is not acceptable then we will have a company with an US FDA approved drug which only people who are wealthy can afford to pay for. Because the treatment is "bespoke" ie. tailored to a patient's own DNA the manufacturing process is not as simple as a drug which is mass manufactured.
what's the risk? ...... it works!, page-16
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.020(6.67%) |
Mkt cap ! $464.8M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 32.3¢ | 30.0¢ | $1.040M | 3.328M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 42705 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |